Ultragenyx Pharmaceutical (RARE) Goodwill & Intangibles (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Goodwill & Intangibles data on file, last reported at $218.0 million in Q1 2026.

• Quarterly Goodwill & Intangibles fell 1.33% year-over-year to $218.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $218.0 million (down 1.33% YoY) and the FY2025 annual result came in at $220.0 million, down 0.9% from the prior year.
• Goodwill & Intangibles retreated to $218.0 million in Q1 2026 per RARE's latest filing, from $220.0 million in the prior quarter.
• Across five years, Goodwill & Intangibles topped out at $222.0 million in Q4 2024 and bottomed at $201.7 million in Q3 2023.
• The 5-year median for Goodwill & Intangibles is $209.5 million (2024), against an average of $210.6 million.
• The widest annual swing landed in 2022, when Goodwill & Intangibles rose 16.73%; it then declined 1.33% in 2026.
• Tracing RARE's Goodwill & Intangibles over 5 years: stood at $204.5 million in 2022, then gained by 3.01% to $210.7 million in 2023, then gained by 5.37% to $222.0 million in 2024, then slipped by 0.9% to $220.0 million in 2025, then slipped by 0.91% to $218.0 million in 2026.
• Per Business Quant, the three latest RARE Goodwill & Intangibles figures stand at $218.0 million (Q1 2026), $220.0 million (Q4 2025), and $217.3 million (Q3 2025).

Peer Comparison